Leiomyosarcoma

Ankit Mangla; Udit Yadav.

Author Information

Last Update: May 14, 2022.

Go to:

Continuing Education Activity

This activity reviews the evaluation, diagnosis, treatment, and latest advances in the field of leiomyosarcoma. It will discuss the existing literature and present the most recent evidence regarding treatment options available for patients diagnosed with soft-tissue sarcoma/leiomyosarcoma. It will also review the ongoing phase I-II trials and medications currently under evaluation to treat soft-tissue sarcoma/leiomyosarcoma. This activity will also highlight the interprofessional team’s role in managing leiomyosarcoma to optimize patient outcomes.

Objectives:

  • Identify the etiology of leiomyosarcoma.
  • Outline the management options available for leiomyosarcoma.
  • Summarize the latest molecules and clinical trials exploring treatment options for all soft-tissue sarcoma, including leiomyosarcoma.
  • Explain interprofessional team strategies for improving care coordination and communication to advance leiomyosarcoma and improve outcomes.

https://www.ncbi.nlm.nih.gov/books/NBK551667/

Non-Uterine Research Updates-

Soft Tissue Sarcoma

 

NLMSF Empowering patients through information / education / support

2024

TRANSLATIONAL CANCER MECHANISMS AND THERAPY| MAY 15 2024
Developing Novel Genomic Risk Stratification Models in Soft Tissue and Uterine Leiomyosarcoma 

Josephine K. Dermawan  Clin Cancer Res (2024) 30 (10): 2260–2271.  https://doi.org/10.1158/1078-0432.CCR-24-0148

 

2023

New Therapeutics for Soft TissueSarcomas – Overview of current Immunotherapy for future direction of STS 14 May 2023
Gyuhee Seong   and   Sandra D’Angelo

High Grade Sarcomas with Myogenic Differentiation Harboring Hotspot PDGFRB Mutations  (May 2023)
https://www.sciencedirect.com/science/article/abs/pii/S089339522300008X
NOTE:   LMS discussed in this article

The Biology and Treatment of LMS Apr 2023

Targeting the Molecular and Immunologic Features of Leiomyosarcoma (31 Mar 2023)
https://www.mdpi.com/2072-6694/15/7/2099

Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is aTherapeutic Strategy for Sarcomas That Can Be Monitoredin Real Time (15 Mar 2023) This research done at MD Anderson Cancer Center was supported by the NLMSF https://pubmed.ncbi.nlm.nih.gov/36603130/

Not All Leiomyosarcomas Are the Same: How to Best Classify LMS (8 Mar 2023) https://link.springer.com/article/10.1007/s11864-023-01067-2

Therapeutic advances in leiomyosarcoma Kristine Lacuna; Sminu Bose, Mathew Ingham, Gary Schwartz (8 Mar 2023) 2023)https://www.frontiersin.org/articles/10.3389/fonc.2023.1149106/full

Clinical characteristics of sarcoma cases in which long-term disease control was achieved with trabectedin treatment: A retrospective study:(1 Mar 2023)
https://pubmed.ncbi.nlm.nih.gov/36857355/

Emerging Trends in Immunotherapy for Adult Sarcomas
Marium HusainLuxi ChenDavid LiebnerJoal BeaneMark RubinsteinRaphael PollockClaire VerschraegenGabriel Tinoco

The Oncologist, oyad052, https://doi.org/10.1093/oncolo/oyad052
Published: 1 March 2023
 
Jonathan Trent, MD, PhD. Sylvester Comprehensive Cancer Center, Sarcoma Center, Miami, FL

Presentation to the Patient – Family Advocacy Network:  Use of Trabectedin in the Treatment of LMS (29 Jan 2023) Hosted by the NLMSF. 
Video recording: https://youtu.be/efuZXkaRncQ

 

2022:

Molecular subtypes of leiomyosarcoma: Moving toward a consensus (2 Nov 2022)
https://onlinelibrary.wiley.com/doi/full/10.1002/ctd2.149

Landmark Series: A Review of Landmark Studies in the Treatment of Primary Localized Retroperitoneal Sarcoma 
(2 Nov 2022)  https://link.springer.com/article/10.1245/s10434-022-12517-w

CLINICAL TRIALS: TARGETED THERAPY (2 Aug 2022)
Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma
https://aacrjournals.org/clincancerres/article-abstract/28/15/3225/707113/Phase-II-Clinical-Trial-of-Eribulin-Gemcitabine?redirectedFrom=fulltext

Phase II Clinical Trial of Eribulin–Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma (2 Aug 2022)

A phase Ib/II study of the combination of lenvatinib (L) and eribulin (E) in advanced liposarcoma (LPS) and leiomyosarcoma (LMS) (LEADER): Efficacy updates. (2 Aug 2023)

 Retroperitoneal LMS Nomogram Model (3 Jul 2022)

Sounding the Alarm on Leiomyosarcoma Recurrence: Role of Circulating Tumor DNA Kasper B, Wilky BA. Researchers of the NLMSF-SPAEN International LMS Research Roundtable – Executive Committee and Workgroup Leadership (13 Jun 2022)

PRESS RELEASE NEWS  from Dr. Brian Van Tine about UNESBULIN: for LMS:  (3 Jun 2022)
https://ir.ptcbio.com/…/preliminary-results-presented…Preliminary Results Presented at ASCO Demonstrated Promising Clinical Efficacy with Unesbulin in Leiomyosarcoma Study

Surgical management strategy for leiomyosarcoma of Zone I-II inferior vena cava: A case series  (3 Jun 2022)   https://pubmed.ncbi.nlm.nih.gov/35665732/

Article by Dr. Matthew Hemming in the Journal of TRANSLATIONAL CANCER MECHANISMS AND THERAPY| 
Preclinical Modeling of Leiomyosarcoma Identifies Susceptibility to Transcriptional CDK Inhibitors through Antagonism of E2F-Driven Oncogenic Gene Expression (1 Jun 2022)
https://aacrjournals.org/clincancerres/article-abstract/28/11/2397/698931/Preclinical-Modeling-of-Leiomyosarcoma-Identifies?redirectedFrom=fulltextz
Note:  This research publication update relates to a research project being funded by the NLMSF being done by Dr. Matt Hemming 

Preoperative Differentiation of Uterine Leiomyomas and Leiomyosarcomas: Current Possibilities and Future Directions (13 Apr 2022)
Brief Summary of the research update: https://pubmed.ncbi.nlm.nih.gov/35454875/
The complete publication (1 Apr 2022): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9029111/

Here is the conclusion:
Conclusion of the study: The review of current literature led to the conclusion that we still have no reliable method to distinguish leiomyomas and leiomyosarcomas preoperatively. The studies in this field have, in most cases, retrospective design and the number of cases seems to be insufficient to achieve conclusive results. The rarity of malignant myometrial lesions is an obvious reason that explains such a situation.
However, on the horizon, we can identify new game-changing options that have the potential to revolutionize our practice in cases of myometrial lesions.
On one hand, there are many ambitious researchers introducing novel multi-parametric diagnostic scales, having promising performances in differentiating such lesions.
On the other hand, the recent advancement of machine learning and artificial intelligence constitute promising novel tools that give hope that we can solve this problem completely. Nowadays, the biggest challenge for researchers and clinicians is organizing multicenter databases that include numerous cases of both LM and LMS, and using them for the development and validation of these novel tools.

What Clinical Trials Are Needed for Treatment of Leiomyosarcoma? (11 Mar 2022)

Proteomic and Metabolomic Profiling in Soft Tissue Sarcomas
Current Treatment Options in Oncology (2022)Cite this article (16 Feb 2022)

Surgical resection of leiomyosarcoma of the inferior vena cava: A case series and literature review (Dec 2021)

Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas ( 1 Aug 2021)

2021:

Large scale multiomic analysis suggests mechanisms of resistance to immunotherapy in leiomyosarcoma.(ASCO Abstract 2021)

Multiomic analysis to reveal distinct molecular profiles of uterine and nonuterine leiomyosarcoma. (ASCO Abstract 2021)

2020:

2019: 

2018:

Soft Tissue and Uterine Leiomyosarcoma
Suzanne George,  César Serrano, Martee L. Hensley, and Isabelle Ray-Coquard (10 Jan 2018)

N L M S F 2024 RFP Announcement: Call for Leiomyosarcoma Research Grant Proposals for 2025-2026 Funding 

Request for Proposals: The National Leiomyosarcoma Foundation

Introduction : The National Leiomyosarcoma Foundation (NLMSF) is dedicated to meeting the needs of leiomyosarcoma (LMS) patients, caregivers and families through education and research. In order to facilitate advances in the treatment of LMS through research, the NLMSF is accepting proposals for pilot studies that will launch “out of the box” ideas and new research trajectories to move the field forward.

Find all the 2024 RFP details at this link.         Click Here

_____________________________________________________________________________________________________________________

 

Congratulations to the NLMSF Research Grantees for 2023 and 2024

 
                                                                       
 
Joanna Pryzbyl , PhD.                                                              

McGill University, Montreal,
Quebec, Canada

Development of the Multi-Omic Liquid Biopsy Assay
for the Pre-Operative Diagnosis of Uterine
Leiomyosarcoma and Benign Leiomyoma

Priya Chudasama, Ph.D.
German Cancer Research Center
Heidelberg, Germany
 
Spatial Heterogeneity and Therapeutic Implications of
Activated Telomere Maintenance Mechanisms in
Leiomyosarcoma